Over the last 25 years, contract manufacturing organizations (CMOs) have played an increasingly important role in the pharmaceutical industry. The need to decrease time to market, improve process efficiency, and reduce costs are all crucial reasons why pharma companies have an increasing use for CMOs – and they’re the same key factors that have propelled the growth of the outsourcing market and will continue to propel its growth over the coming years. A November 2016 study from Industry Standard Research Reports reveals that life sciences companies now outsource two-thirds of their manufacturing activities for CMOs. For small to mid-sized companies – where outsourcing manufacturing isn’t just a convenience, it’s a necessity – that figure is even higher: up to 80% in 2015. These partnerships often last many years and have the potential to either constrict or add considerable value to a company’es growth. Success relies, of course, on choosing the right manufacturer. But once the contract is signed, what are the responsibilities of the client to ensure effective collaboration and maximum productivity? Recognizing how the relationship can break down on the client’s side is a crucial step in reducing risks.
Read More →Interview with Victoria Yeager, Head of Contracts and Compliance, Genentech
We were honored to have Victoria Yeager, Head of Global Pharma Procurement Contracts & Compliance at Genentech, join us as a key speaker at the 2017 American Pharma Outsourcing Summit where she discussed “To Outsource or Not to Outsource? Developing Your Ideal Contract Support Model.” We sat down with Victoria at the summit to gather her insights on the current and future state of the pharma outsourcing industry. Watch the full video interview above or read a partial transcript below. What do the next 5 years in the outsourcing space look like? The next five years in the outsourcing space, in my opinions, looks like more outsourcing. I think if we go back to the (Peter) Drucker Quote – to paraphrase – “do what you do best and outsource the rest.” I think that’s going be even more and more important and the reason is, in the pharma industry, things are changing so fast we have to be agile, and so allowing companies to focus on what they do best and their partners to focus on what they do best will allow everything to operate much more smoothly and agilely, which I think is really important.
Read More →